

Interactions with HBV Treatment

Charts revised December 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Anticoagulant, Antiplatelet & Fibrinolytic									
Abciximab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acenocoumarol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anagrelide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Apixaban	◆	◆	◆	◆	◆	◆	◆	◆	◆
Caplacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clopidogrel	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dabigatran	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Danaparoid	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Edoxaban	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluindione	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prasugrel	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rivaroxaban	◆	◆	◆	◆	◆	◆	◆	◆	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ticlopidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Warfarin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anticonvulsants									
Carbamazepine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clonazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethosuximide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Perampanel	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenobarbital	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenytoin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆	◆	◆	◆	◆

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Anticonvulsants continued									
Tiagabine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Valproic acid (Divalproex)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants									
Agomelatine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dosulepin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mianserin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Moclobemide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nefazodone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenelzine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Reboxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tianeptine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antidiabetics									
Acarbose	◆	◆	◆	◆	◆	◆	◆	◆	◆
Albiglutide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alogliptin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Canagliflozin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dapagliflozin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dulaglutide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Empagliflozin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Exenatide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glibenclamide (Glyburide)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gliclazide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glimepiride	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HBV Treatment

Charts revised December 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Anxiolytics/Hypnotics/Sedatives									
Alprazolam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amobarbital	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromperidol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Buspirone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobazam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clorazepate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clotiapine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Midazolam (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Midazolam (parenteral)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Quazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Beta Blockers									
Atenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisoprolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carvedilol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Celiprolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Labetalol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metoprolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nebivolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Oxprenolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pindolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propranolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sotalol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Timolol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisphosphonates									
Alendronic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clodronate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ibandronic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pamidronate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risedronate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zoledronic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bronchodilators									
Acclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Formoterol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Reslizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Theophylline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tiotropium	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium Channel Blockers									
Amlodipine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diltiazem	◆	◆	◆	◆	◆	◆	◆	◆	◆
Felodipine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicardipine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nifedipine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nisoldipine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitrendipine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Verapamil	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Cancer Therapies									
Abiraterone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acalabrutinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Afatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alectinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alpelisib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amivantamab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Asciminib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Asparaginase	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atezolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Avapritinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Avelumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Axitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Azacitidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Belantamab mafodotin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bendamustine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bevacizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bexarotene	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bicalutamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Blinatumomab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bortezomib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bosutinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brentuximab vedotin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Capecitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carboplatin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carfilizomib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cemiplimab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cetuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorambucil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cisplatin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclophosphamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Daratumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dasatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dinutuximab beta	◆	◆	◆	◆	◆	◆	◆	◆	◆
Doxorubicin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Durvalumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elotuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eltaninib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Enzalutamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epcoritamab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epirubicin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erlotinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Estramustine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etoposide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Everolimus	◆	◆	◆	◆	◆	◆	◆	◆	◆
Exemestane	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fludarabine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gefitinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gemcitabine	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HBV Treatment

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Cancer Therapies continued									
Gemtuzumab ozogamicin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glofitamab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydroxyurea (Hydroxycarbamide)	■	■	■	■	■	■	■	■	■
Ibrutinib	◆	◆	◆	▲	▲	▲	◆	◆	◆
Idarubicin	◆	◆	◆	■	■	■	◆	◆	◆
Idelalisib	◆	◆	◆	▲	▲	▲	◆	◆	◆
Imatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Inotuzumab ozogamicin	◆	◆	◆	■	■	■	◆	◆	◆
Ipilimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Irinotecan	◆	◆	◆	■	■	■	◆	◆	◆
Isatuximab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ixazomib	◆	◆	◆	■	■	■	◆	◆	◆
Lapatinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Letrozole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loncastuximab tesirine	◆	◆	◆	■	■	■	◆	◆	◆
Medroxyprogesterone (oncology)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mercaptopurine	◆	◆	◆	■	■	●	◆	◆	◆
Mesna	■	■	◆	◆	◆	◆	◆	◆	■
Methotrexate	■	■	◆	■	■	■	◆	◆	■
Mitoxantrone	◆	◆	◆	■	■	■	◆	◆	◆
Mogamulizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nilotinib	◆	◆	◆	◆	◆	◆	◆	◆	◆
Niraparib	◆	◆	◆	■	■	■	◆	◆	◆
Nivolumab	◆	◆	◆	■	■	■	◆	◆	◆
Obinutuzumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ofatumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Olaparib	◆	◆	▲	▲	▲	▲	▲	▲	◆
Olaratumab	◆	◆	◆	■	■	■	◆	◆	◆
Osimertinib	◆	◆	◆	■	■	■	◆	◆	◆
Oxaliplatin	▲	▲	▲	■	■	■	◆	◆	■
Paclitaxel	◆	◆	◆	■	■	■	◆	◆	◆
Panitumumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Panobinostat	◆	◆	▲	▲	▲	▲	◆	◆	▲
Pertuzumab	◆	◆	◆	■	■	■	◆	◆	◆
Pomalidomide	◆	◆	◆	■	■	■	◆	◆	◆
Ponatinib	◆	◆	◆	■	■	■	◆	◆	■
Ramucirumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rituximab	◆	◆	◆	■	■	■	◆	◆	◆
Sacituzumab Govitecan	◆	◆	◆	■	■	■	◆	◆	◆
Retifanlimab	◆	◆	◆	■	■	■	◆	◆	◆
Ruxolitinib	◆	◆	◆	■	■	■	▲	▲	◆
Sunitinib	◆	◆	◆	■	■	■	◆	◆	◆
Tamoxifen	◆	◆	◆	◆	◆	◆	◆	◆	◆
Temsirolimus	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tepotinib	◆	◆	◆	◆	◆	◆	■	■	◆
Tisotumab vedotin	◆	◆	◆	■	■	■	◆	◆	◆
Tivozanib	◆	◆	◆	■	■	■	◆	◆	◆
Trametinib	◆	◆	◆	◆	◆	◆	■	■	◆
Trastuzumab	◆	◆	◆	■	■	■	◆	◆	◆
Trastuzumab Deruxtecan	◆	◆	◆	■	■	■	◆	◆	◆
Trastuzumab Emtansine	◆	◆	◆	■	■	■	◆	◆	◆
Trifluridine/tipiracil	◆	◆	◆	■	■	■	◆	◆	◆
Vinblastine	◆	◆	◆	■	■	■	◆	◆	◆
Vincristine	◆	◆	◆	■	■	■	◆	◆	◆
Vinorelbine	◆	◆	◆	■	■	■	◆	◆	◆

For personal use only. Not for distribution.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Contraceptives and Hormone Replacements									
Conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel/ethinylestradiol (COC) (>20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desogestrel/ethinylestradiol (COC) (≤20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dienogest	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone/estradiol (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone/ethinylestradiol (COC) (>20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Drospirenone/ethinylestradiol (COC) (≤20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dydrogesterone/estradiol (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Estradiol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethinylestradiol (>20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ethinylestradiol (≤20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etonogestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etonogestrel (vaginal ring)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gestodene/ethinylestradiol (COC) (>20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (Emergency Contraception)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (IUD)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel/ethinylestradiol (COC) (>20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levonorgestrel/ethinylestradiol (COC) (≤20 µg)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (depot)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone/conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone/estradiol (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Micronized progesterone (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norelgestromin/ethinylestradiol (patch)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone) (depot injection)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone) (POP)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/ethinylestradiol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/mestranol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestimate/ethinylestradiol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel/conjugated estrogens (HRT)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Norgestrel/ethinylestradiol (COC)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Testosterone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Erectile Dysfunction Agents									
Sildenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Yohimbine	◆	◆	◆	▲	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HBV Treatment

Charts revised December 2024. Full information available at www.hep-druginteractions.org

Page 6 of 6

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Gastrointestinal Agents									
Aluminium hydroxide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Alverine citrate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aprepitant	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cisapride	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆	◆	◆	◆	◆
Docusate sodium	◆	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Droperidol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lafutidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Linacotide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lubiprostone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Macrogol	▲	▲	▲	◆	◆	▲	▲	▲	▲
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nizatidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ondansetron	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranitidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Roxatidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trimebutine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vonoprazan	◆	◆	◆	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
HCC Therapies									
Atezolizumab + bevacizumab	◆	◆	◆	▲	▲	▲	◆	◆	◆
Lenvatinib	◆	◆	◆	▲	▲	▲	◆	◆	◆
Pembrolizumab	◆	◆	◆	▲	▲	▲	◆	◆	◆
Regorafenib	◆	◆	◆	▲	▲	▲	◆	◆	◆
Sorafenib	◆	◆	◆	▲	▲	▲	◆	◆	◆
Hepatitis B Drugs									
Adefovir	◆	▲	◆	▲	▲	◆	◆	◆	◆
Entecavir	▲	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2a	◆	◆	◆	◆	n/a	◆	◆	◆	◆
Peginterferon alfa-2b	◆	◆	◆	n/a	◆	◆	◆	◆	◆
Ribavirin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide (TAF)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis C Drugs (Direct Acting Antivirals)									
Daclatasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆
Elbasvir/Grazoprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆
OBV/PTV/r	◆	◆	◆	◆	◆	◆	◆	◆	◆
OBV/PTV/r + Dasabuvir	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ravidasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir (SOF)	◆	◆	◆	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir	◆	◆	◆	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir/Voxilaprevir	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hepatitis D Entry Inhibitor									
Bulevirtide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Herbals/Supplements/Vitamins									
Aloe vera	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ashwagandha (Withania somnifera)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Black cohosh (A. racemosa)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (U. tomentosa)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	◆	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
▲	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HBV Treatment

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Illicit/Recreational									
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etizolam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	◆	◆	◆	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mephedrone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nitazenes	◆	◆	◆	▲	▲	◆	◆	◆	◆
Nicotine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Xylazine	◆	◆	◆	▲	▲	◆	◆	◆	◆
Immunosuppressants									
Abatacept	◆	◆	◆	■	■	■	◆	◆	◆
Adalimumab	◆	◆	◆	▲	▲	■	◆	◆	◆
Alemtuzumab	◆	◆	◆	■	■	■	◆	◆	◆
Anakinra	◆	◆	◆	■	■	■	◆	◆	◆
Azathioprine	◆	◆	◆	■	■	■	◆	◆	◆
Baricitinib	◆	◆	◆	■	■	■	◆	◆	◆
Basiliximab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Belimumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brodalumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	■	■	■	◆	◆	◆
Ciclosporin	◆	◆	◆	◆	◆	◆	■	■	■
Eculizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆	◆	◆	◆
Golimumab	◆	◆	◆	■	■	■	◆	◆	◆
Guselkumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Infliximab	◆	◆	◆	◆	◆	■	◆	◆	◆
Ixekizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lenalidomide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	◆	■	■	■	◆	◆	■
Pirfenidone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ravulizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	■	■	■	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Siltuximab	◆	◆	◆	■	■	■	◆	◆	◆
Sirolimus	◆	◆	◆	◆	◆	◆	◆	◆	▲
Tacrolimus	◆	◆	◆	◆	◆	◆	◆	▲	◆
Tildrakizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	■	■	■	◆	◆	◆
Tralokinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ublituximab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Upadacitinib	◆	◆	◆	■	■	■	◆	◆	◆
Ustekinumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Vedolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lipid Lowering Agents									
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	◆	◆	◆	◆	◆	◆	■	◆	◆
Bempedoic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bezafibrate	◆	◆	◆	◆	◆	◆	■	◆	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	■	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	◆	◆	◆	■	◆	◆
Gemfibrozil	◆	◆	◆	◆	◆	◆	■	◆	◆
Icosapent ethyl	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lovastatin	◆	◆	◆	◆	◆	◆	■	◆	◆
Omega-3-6-9 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	◆	◆	■	◆	◆
Pravastatin	◆	◆	◆	◆	◆	◆	■	◆	◆
Rosuvastatin	◆	◆	◆	◆	◆	◆	■	◆	◆
Simvastatin	◆	◆	◆	◆	◆	◆	■	◆	◆

For personal use only. Not for distribution.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Other Drugs									
Acamprosate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Acetazolamide	■	■	◆	◆	◆	◆	◆	◆	■
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	▲	▲	▲	◆	◆	▲	▲	▲	▲
Allopurinol	◆	◆	◆	■	■	■	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bamlanivimab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bethahistine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brimonidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Burosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cannabidiol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Casirivimab/imdevimab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	◆	◆	▲	◆	◆
Colestyramine	▲	▲	▲	◆	◆	▲	▲	▲	▲
Conivaptan	◆	◆	◆	◆	◆	◆	◆	◆	◆
Convalescent plasma (COVID-19)	◆	◆	◆	◆	◆	◆	◆	◆	◆
COVID-19 vaccinations	◆	◆	◆	◆	◆	◆	◆	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Cyproterone acetate	◆	◆	◆	◆	■	■	◆	◆	◆
Cytisine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	■	■	◆	◆	◆	◆
Donepezil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dorzolamide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eliglustat	◆	◆	◆	◆	■	◆	◆	◆	◆
Emicizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Faricimab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glucose monohydrate (IV)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Goserelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Guanfacine	◆	◆	▲	◆	◆	◆	◆	◆	◆
Idarucizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Influenza vaccine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Interferon beta	◆	◆	◆	●	●	■	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HBV Treatment

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF.

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Other Drugs Continued									
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanadelumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lanreotide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Levothyroxine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	▲	◆	◆	◆	◆
Lofexidine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Lumacaftor/Ivacaftor	◆	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium	◆	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	◆	◆	◆	■	■	■	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nafidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	▲	▲	▲	◆	◆	▲	▲	▲	▲
Penicillamine	◆	◆	◆	◆	◆	◆	■	◆	■
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	■	■	■	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pyridostigmine	▲	▲	▲	◆	◆	◆	◆	◆	▲
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Romosozumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Rozanolixizumab	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sevelamer	▲	▲	▲	◆	◆	▲	▲	▲	▲
Strontium ranelate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Thalidomide	◆	◆	◆	■	■	■	◆	◆	◆
Triptorelin	◆	◆	◆	■	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆	◆

	ADV	ETV	LAM	PEG IFN alfa-2a	PEG IFN alfa-2b	RBV	TBV	TAF	TDF
Oxytocics									
Ergometrine (ergonovine)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mifepristone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆	◆
Parkinsonism Agents									
Benzotropine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pramipexole	◆	◆	▲	◆	◆	◆	◆	◆	◆
Procyclidine	◆	◆	▲	◆	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	◆	◆	◆	◆	◆
PBC Agents									
Obeticholic acid	▲	◆	◆	◆	◆	◆	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆	◆	◆	◆	◆
Steroids									
Beclomethasone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	◆	◆	◆	◆	◆	◆	■	◆	◆
Budesonide	◆	◆	◆	◆	◆	◆	▲	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone ≤16 mg	◆	◆	◆	◆	◆	◆	■	◆	◆
Dexamethasone >16 mg	◆	◆	◆	◆	◆	◆	■	◆	◆
Fludrocortisone	◆	◆	◆	◆	◆	◆	■	◆	◆
Flunisolide	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone	◆	◆	◆	◆	◆	◆	▲	◆	◆
Mometasone	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	◆	■	◆	◆
Triamcinolone	◆	◆	◆	◆	◆	◆	■	◆	◆
Urological Agents									
Alfuzosin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆	◆	◆	◆	◆
Mirabegron	◆	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Solifenacin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	◆	◆	◆	◆
Trospium	◆	◆	▲	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.